Q2 2020
Released Aug 5, 2020, after the close
10-Q filed Aug 5, 2020, 36 days after period end · 0001493152-20-014717
Q2 2020 · 10-Q
Revenue$1.58M$1.58M −31.7% vs Q2 2019−37.6% vs Q1 2020
Net Income-$1.66M-$1.66M N/M vs Q2 2019N/M vs Q1 2020
EPS Diluted-$0.19-$0.19 N/M vs Q2 2019N/M vs Q1 2020
Gross Profit$895,000−34.5%
Operating Income-$1,598,000N/M
Operating Cash Flowderived-$1,720,000N/M
Margins · derived
Gross margin56.8%−2.4 pt vs Q2 2019
Operating margin-101.3%−63.7 pt vs Q2 2019
Net margin-105.1%−64.3 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $1.58M | $2.31M | $1.37M | $859.00K |
| Net Income | -$1.66M | -$942.00K | -$682.00K | -$786.00K |
| EPS Diluted | -$0.19 | -$0.14 | -$0.10 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR